﻿<?xml version="1.0" encoding="UTF-8"?>
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>Nickan Research Institute</PublisherName>
      <JournalTitle>Immunopathologia Persa</JournalTitle>
      <Issn>2423-8015</Issn>
      <Volume>9</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2023</Year>
        <Month>01</Month>
        <DAY>01</DAY>
      </PubDate>
    </Journal>
    <ArticleTitle>Tumor budding in gastric adenocarcinoma; reflections on tumor microenvironment and programmed death ligand 1 (PD-L1) expression</ArticleTitle>
    <FirstPage>e31365</FirstPage>
    <LastPage>e31365</LastPage>
    <ELocationID EIdType="doi">10.34172/ipp.2022.31365</ELocationID>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Safaa M.M.</FirstName>
        <LastName>Abd El Khalek</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0002-2165-8878</Identifier>
      </Author>
      <Author>
        <FirstName>Mariam I.</FirstName>
        <LastName>Halim</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0002-0501-7827</Identifier>
      </Author>
    </AuthorList>
    <PublicationType>Journal Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.34172/ipp.2022.31365</ArticleId>
    </ArticleIdList>
    <History>
      <PubDate PubStatus="received">
        <Year>2022</Year>
        <Month>01</Month>
        <Day>27</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2022</Year>
        <Month>05</Month>
        <Day>28</Day>
      </PubDate>
    </History>
    <Abstract>Introduction: The significance of tumor budding and programmed death ligand 1 (PD-L1) has not been established in gastric adenocarcinoma (GAC). Objectives: This study evaluated tumor budding and PD-L1 expression with regard to tumor microenvironment, clinicopathologic parameters, and overall survival in GAC. Patients and Methods: Totally, 102 GAC cases were assessed immunohistochemically. The associations of tumor budding and PD-L1 with clinicopathologic features, tumor-infiltrating lymphocytes (TILs), tumor stroma percentage (TSP), and overall survival were analyzed. Results: High tumor budding (42.2% of cases) was correlated with distal tumor location, large tumor size, Helicobacter pylori infection, poor differentiation (P = 0.0008, 0.033, 0.011, and 0.005, respectively), lymphovascular invasion, high tumor and nodal stages, and TSP (all P &lt; 0.0001). Tumor budding was highest in the low TILs/high TSP group. PD-L1 expression (43.1% of cases) was correlated with proximal location (p = 0.00021), poor differentiation (P = 0.036), N stage (P = 0.049), high TILs (P &lt; 0.0001), and low tumor budding (P = 0.002). PD-L1 expression was highest in the low tumor budding / high TILs category (P &lt; 0.0001). Cox regression showed that high tumor budding (hazard ratio [HR]: 15.282, P = 0.024, 95% confidence interval [CI]: 1.441–162.069) and positive PD-L1 (HR: 7.502, P = 0.015, 95% CI: 1.469–38.31) were independent prognostic factors for overall survival. Conclusion: Tumor budding is correlated with poor prognostic parameters, whereas PD-L1 expression is inversely correlated with tumor budding. Both are independent predictors of short overall survival. Anti-PD-L1 immunotherapy could be effective in GAC with nodal metastasis, especially cases with high TILs and low tumor budding.</Abstract>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Gastric adenocarcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Tumor budding</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">PD-L1 expression</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Tumor microenvironment</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Prognosis</Param>
      </Object>
    </ObjectList>
  </Article>
</ArticleSet>